Genmab A/S (NASDAQ:GMAB) Reaches New 52-Week Low - Here's What Happened

Shares of Genmab A/S (NASDAQ:GMAB - Get Free Report) reached a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $23.23 and last traded at $23.25, with a volume of 645297 shares trading hands. The stock had previously closed at $23.66.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Truist Financial decreased their target price on Genmab A/S from $53.00 to $50.00 and set a "buy" rating on the stock in a research note on Monday, September 9th. BTIG Research boosted their price target on shares of Genmab A/S from $46.00 to $47.00 and gave the stock a "buy" rating in a research note on Thursday, June 27th. JPMorgan Chase & Co. reiterated a "neutral" rating on shares of Genmab A/S in a research note on Tuesday, August 20th. Redburn Atlantic started coverage on Genmab A/S in a research note on Tuesday, October 8th. They set a "buy" rating for the company. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $50.00 price target on shares of Genmab A/S in a research report on Friday, September 20th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, Genmab A/S has an average rating of "Moderate Buy" and an average target price of $45.20.

Genmab A/S Stock Performance

The firm has a 50-day moving average price of $26.03 and a two-hundred day moving average price of $27.26. The firm has a market cap of $15.33 billion, a price-to-earnings ratio of 19.32, a price-to-earnings-growth ratio of 0.71 and a beta of 0.98.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its earnings results on Thursday, August 8th. The company reported $0.22 EPS for the quarter, missing analysts' consensus estimates of $0.29 by ($0.07). Genmab A/S had a net margin of 29.06% and a return on equity of 17.48%. The company had revenue of $779.50 million during the quarter, compared to analysts' expectations of $734.60 million. Research analysts anticipate that Genmab A/S will post 1.27 earnings per share for the current year.

Hedge Funds Weigh In On Genmab A/S

Institutional investors have recently modified their holdings of the business. DDD Partners LLC purchased a new position in shares of Genmab A/S during the 2nd quarter worth approximately $8,860,000. Capital International Investors increased its holdings in Genmab A/S by 7.8% during the 1st quarter. Capital International Investors now owns 4,373,277 shares of the company's stock valued at $130,805,000 after acquiring an additional 315,355 shares in the last quarter. Cubist Systematic Strategies LLC raised its position in shares of Genmab A/S by 109.7% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 278,541 shares of the company's stock worth $7,000,000 after purchasing an additional 145,689 shares during the last quarter. Renaissance Technologies LLC raised its holdings in shares of Genmab A/S by 7.6% in the second quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company's stock worth $36,752,000 after acquiring an additional 103,859 shares during the last quarter. Finally, Sanctuary Advisors LLC purchased a new position in Genmab A/S in the 2nd quarter valued at about $1,354,000. 7.07% of the stock is owned by institutional investors and hedge funds.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.